BDH1抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P08067(BDH1 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08067(BDH1 Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

The BDH1 antibody is designed to target β-hydroxybutyrate dehydrogenase 1 (BDH1), a mitochondrial enzyme encoded by the *BDH1* gene. BDH1 plays a critical role in ketone body metabolism, catalyzing the reversible conversion of β-hydroxybutyrate (β-HB) to acetoacetate (AcAc), a key energy source during fasting or metabolic stress. This enzyme is highly expressed in tissues with high energy demands, such as the liver, heart, and brain, and is essential for maintaining systemic energy homeostasis. Dysregulation of BDH1 has been implicated in metabolic disorders, including diabetes, obesity, and cardiovascular diseases, as well as in cancer progression due to altered ketone utilization in tumor microenvironments.

The BDH1 antibody is widely used in research to study protein expression, localization, and function in various physiological and pathological contexts. It is employed in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess BDH1 levels in tissue samples or cell lines. Researchers also utilize this antibody to explore BDH1's role in metabolic reprogramming, particularly in cancers where cells shift toward ketone metabolism for survival. Additionally, it aids in investigating potential therapeutic strategies targeting ketolytic pathways. Commercial BDH1 antibodies are typically validated for specificity and sensitivity, ensuring reliable detection across species, including human and mouse models. Understanding BDH1's mechanisms through such tools may offer insights into novel biomarkers or treatments for metabolic and oncological diseases.